W P McGuire

Summary

Publications

  1. ncbi request reprint Is it time for some new approaches for treating advanced ovarian cancer?
    William P McGuire
    J Natl Cancer Inst 98:1024-6. 2006
  2. ncbi request reprint Current aspects of adjuvant therapy of early stage ovarian cancer
    W P McGuire
    University of Mississippi School of Medicine, Atlanta, GA, USA
    Zentralbl Gynakol 120:93-7. 1998
  3. ncbi request reprint The Gynecologic Oncology Group experience in ovarian cancer
    W P McGuire
    University of Mississippi, Jackson, USA
    Ann Oncol 10:29-34. 1999
  4. ncbi request reprint Current status of taxane and platinum-based chemotherapy in ovarian cancer
    William P McGuire
    Oncology Service Line, Franklin Square Hospital, Baltimore, MD 21237, USA
    J Clin Oncol 21:133s-135s. 2003
  5. pmc Primary ovarian cancer chemotherapy: current standards of care
    W P McGuire
    Franklin Square Hospital Center, Baltimore, MD 21237, USA
    Br J Cancer 89:S3-8. 2003
  6. ncbi request reprint Contemporary management of ovarian cancer
    D D Im
    The Gynecologic Oncology Center, Mercy Medical Center, Baltimore, Maryland 21202, USA
    Obstet Gynecol Clin North Am 28:759-73. 2001
  7. ncbi request reprint Clear cell carcinoma of the ovary: a remarkable case
    J Giblin
    The Emory Clinic, Atlanta, Georgia, USA
    Am J Clin Oncol 24:99-100. 2001
  8. ncbi request reprint Recurrent ovarian cancer
    Mohan K Tummala
    Greenbaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Clin Adv Hematol Oncol 3:723-36. 2005
  9. ncbi request reprint Liposomal anthracycline treatment for ovarian cancer
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 31:91-105. 2004
  10. ncbi request reprint Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Ft Sam
    J Clin Oncol 25:3621-7. 2007

Detail Information

Publications21

  1. ncbi request reprint Is it time for some new approaches for treating advanced ovarian cancer?
    William P McGuire
    J Natl Cancer Inst 98:1024-6. 2006
  2. ncbi request reprint Current aspects of adjuvant therapy of early stage ovarian cancer
    W P McGuire
    University of Mississippi School of Medicine, Atlanta, GA, USA
    Zentralbl Gynakol 120:93-7. 1998
    ..More than two decades of studies are reviewed and conclusions offered. Additionally, important issues for the future therapy of this disease are presented...
  3. ncbi request reprint The Gynecologic Oncology Group experience in ovarian cancer
    W P McGuire
    University of Mississippi, Jackson, USA
    Ann Oncol 10:29-34. 1999
    ....
  4. ncbi request reprint Current status of taxane and platinum-based chemotherapy in ovarian cancer
    William P McGuire
    Oncology Service Line, Franklin Square Hospital, Baltimore, MD 21237, USA
    J Clin Oncol 21:133s-135s. 2003
    ..A separate article discusses the docetaxel-platinum doublet and how that might be considered an appropriate option for first-line therapy in patients with advanced, newly diagnosed ovarian cancer...
  5. pmc Primary ovarian cancer chemotherapy: current standards of care
    W P McGuire
    Franklin Square Hospital Center, Baltimore, MD 21237, USA
    Br J Cancer 89:S3-8. 2003
    ..g. docetaxel), other novel agents and new treatment schedules are ongoing...
  6. ncbi request reprint Contemporary management of ovarian cancer
    D D Im
    The Gynecologic Oncology Center, Mercy Medical Center, Baltimore, Maryland 21202, USA
    Obstet Gynecol Clin North Am 28:759-73. 2001
    ..In the new millenium, new therapeutic modalities should enhance the current response rates...
  7. ncbi request reprint Clear cell carcinoma of the ovary: a remarkable case
    J Giblin
    The Emory Clinic, Atlanta, Georgia, USA
    Am J Clin Oncol 24:99-100. 2001
    ..Treatment--and long-term maintenance therapy--with topotecan may be an option in such patients. In this case, the lack of cumulative toxicities allows the patient to maintain her usual daily activities...
  8. ncbi request reprint Recurrent ovarian cancer
    Mohan K Tummala
    Greenbaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Clin Adv Hematol Oncol 3:723-36. 2005
    ..In this article we address these issues with an emphasis on evidence from the available literature and also discuss the clinical trials that are currently underway to resolve these issues...
  9. ncbi request reprint Liposomal anthracycline treatment for ovarian cancer
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 31:91-105. 2004
    ..Proper dosing and monitoring may further enhance tolerability while preserving the efficacy of this versatile agent for ovarian cancer...
  10. ncbi request reprint Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Ft Sam
    J Clin Oncol 25:3621-7. 2007
    ..The purpose of this study was to identify factors predictive of poor prognosis in a similarly treated population of women with advanced EOC...
  11. ncbi request reprint Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group
    David H Moore
    Department of Obstetrics Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 21:4207-13. 2003
    ..The purpose of this study was to determine whether amifostine (WR-2721) prevents or ameliorates clinically significant (grade 2 to 4) neurotoxicity associated with cisplatin and 3-hour paclitaxel chemotherapy. Materials and..
  12. ncbi request reprint Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  13. ncbi request reprint Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Department of Obstetrics and Gynecology, Gynecologic Oncology, Brooke Army Medical Center, Ft Sam Houston, TX, USA
    J Clin Oncol 26:83-9. 2008
    ..To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC)...
  14. ncbi request reprint Ovarian cancer, CA-125 addiction, and informed confusion: much ado about less
    Mohan K Tummala
    J Clin Oncol 25:3570-1. 2007
  15. ncbi request reprint Ovarian cancer and the battle of the specialists
    William P McGuire
    J Clin Oncol 25:3554-5; author reply 3557-8. 2007
  16. ncbi request reprint A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer
    Michael V Seiden
    Gynecologic Oncology Research Program at Dana Farber Partners Cancer Care Program, Boston, MA 02115, USA
    Gynecol Oncol 101:55-61. 2006
    ..To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive prior chemotherapy...
  17. ncbi request reprint CA-125 and early ovarian cancer: does this help the clinician or further muddy the water?
    William P McGuire
    J Clin Oncol 23:5862-4. 2005
  18. ncbi request reprint Perioperative morbidity and the rush to chemotherapy
    William P McGuire
    J Clin Oncol 23:665-6. 2005
  19. ncbi request reprint Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks
    Saroj Vadhan-Raj
    Section of Cytokines and Targeted Therapies, Anderson Cancer Center, Houston, TX 77030, USA
    J Support Oncol 1:131-8. 2003
    ....
  20. ncbi request reprint Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis
    Barry Mirtsching
    Center for Oncology Research and Treatment Dallas, Texas, USA
    Oncology (Williston Park) 16:31-6. 2002
    ..In conclusion, darbepoetin alfa at a dose of 3.0 microg/kg given every 2 weeks safely increases hemoglobin concentration to the same extent as rHuEPO...
  21. doi request reprint Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
    Mohan K Tummala
    Clinical Research Fellow, Clinical Research Branch, National Institute on Aging NIH and Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
    Expert Rev Anticancer Ther 8:1135-47. 2008
    ....